6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group

Tools

Item Type:	Article
Title:	6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group
Creators Name:	Buechner, T., Hiddemann, W., Berdel, W.E., Woermann, B., Schoch, C., Fonatsch, C., Loeffler, H., Haferlach, T., Ludwig, W.D., Maschmeyer, G., Staib, P., Aul, C., Grueneisen, A., Lengfelder, E., Frickhofen, N., Kern, W., Serve, H.L., Mesters, R.M., Sauerland, M.C. and Heinecke, A.
Source:	Journal of Clinical Oncology
ISSN:	0732-183X
Volume:	21
Page Range:	4496-4504
Date:	15 December 2003
Official Publication:	https://doi.org/10.1200/JCO.2003.02.133
PubMed:	View item in PubMed

Repository Staff Only: item control page